A phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions

BACKGROUND: We found that (18)F-2-fluoro-2-deoxy-D-glucose ((18)F-FDG) uptake in malignant lesion was enhanced, and it was decreased in the inflammatory lesion after the use of peroxisome proliferator activated receptor-γ (PPAR-γ) agonist in our previous preclinical study. The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yeon-Hee, Kwon, Seong Young, Kim, Jeonghun, Na, Chang Ju, Choi, Sehun, Min, Jung-Joon, Bom, Hee-Seung, Kim, Young-Chul, Oh, In-Jae, Chae, Han-Jung, Lim, Seok Tae, Sohn, Myung-Hee, Jeong, Hwan-Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583556/
https://www.ncbi.nlm.nih.gov/pubmed/26408008
http://dx.doi.org/10.1186/s13550-015-0128-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583556/
https://www.ncbi.nlm.nih.gov/pubmed/26408008
http://dx.doi.org/10.1186/s13550-015-0128-9

Ejemplares similares